Emily Bodnar
Stock Analyst at HC Wainwright & Co.
(1.02)
# 3,494
Out of 4,681 analysts
243
Total ratings
27.63%
Success rate
-19.94%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Emily Bodnar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BCTX BriaCell Therapeutics | Reiterates: Buy | $15 | $1.04 | +1,342.31% | 11 | Dec 3, 2024 | |
| NVCR NovoCure | Maintains: Buy | $30 → $38 | $30.92 | +22.92% | 17 | Dec 3, 2024 | |
| AGEN Agenus | Reiterates: Neutral | $7 | $3.57 | +96.08% | 11 | Nov 29, 2024 | |
| SANA Sana Biotechnology | Reiterates: Buy | $8 | $2.77 | +189.33% | 8 | Nov 27, 2024 | |
| FEMY Femasys | Reiterates: Buy | $12 | $1.06 | +1,031.01% | 14 | Nov 27, 2024 | |
| PPBT Purple Biotech | Reiterates: Buy | $33 | $6.37 | +418.46% | 14 | Nov 15, 2024 | |
| GNLX Genelux | Maintains: Buy | $32 → $30 | $2.97 | +910.10% | 5 | Nov 15, 2024 | |
| RNAZ TransCode Therapeutics | Reiterates: Buy | $3 | $0.26 | +1,068.68% | 12 | Nov 15, 2024 | |
| INKT MiNK Therapeutics | Reiterates: Buy | $9 | $0.73 | +1,129.34% | 10 | Nov 15, 2024 | |
| SLRN Acelyrin | Maintains: Neutral | $6 → $8 | $4.29 | +86.48% | 11 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $22 | $7.32 | +200.75% | 10 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $7 | $1.24 | +466.80% | 9 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $9.92 | +202.57% | 14 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $0.83 | +1,338.85% | 11 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $1.15 | +247.83% | 6 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $12 | $0.84 | +1,322.98% | 9 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $6 | $2.42 | +148.45% | 14 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $18 | $2.79 | +546.32% | 14 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $95 → $115 | $92.00 | +25.01% | 11 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 → $52 | $22.70 | +129.07% | 5 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $3.96 | +102.18% | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $20 | $16.26 | +23.04% | 3 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $65 | $24.85 | +161.57% | 7 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $6 | $1.51 | +297.35% | 10 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $1.06 | +654.79% | 4 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $3.35 | - | 1 | Apr 25, 2024 |
BriaCell Therapeutics
Dec 3, 2024
Reiterates: Buy
Price Target: $15
Current: $1.04
Upside: +1,342.31%
NovoCure
Dec 3, 2024
Maintains: Buy
Price Target: $30 → $38
Current: $30.92
Upside: +22.92%
Agenus
Nov 29, 2024
Reiterates: Neutral
Price Target: $7
Current: $3.57
Upside: +96.08%
Sana Biotechnology
Nov 27, 2024
Reiterates: Buy
Price Target: $8
Current: $2.77
Upside: +189.33%
Femasys
Nov 27, 2024
Reiterates: Buy
Price Target: $12
Current: $1.06
Upside: +1,031.01%
Purple Biotech
Nov 15, 2024
Reiterates: Buy
Price Target: $33
Current: $6.37
Upside: +418.46%
Genelux
Nov 15, 2024
Maintains: Buy
Price Target: $32 → $30
Current: $2.97
Upside: +910.10%
TransCode Therapeutics
Nov 15, 2024
Reiterates: Buy
Price Target: $3
Current: $0.26
Upside: +1,068.68%
MiNK Therapeutics
Nov 15, 2024
Reiterates: Buy
Price Target: $9
Current: $0.73
Upside: +1,129.34%
Acelyrin
Nov 14, 2024
Maintains: Neutral
Price Target: $6 → $8
Current: $4.29
Upside: +86.48%
Nov 14, 2024
Reiterates: Buy
Price Target: $22
Current: $7.32
Upside: +200.75%
Nov 13, 2024
Maintains: Buy
Price Target: $6 → $7
Current: $1.24
Upside: +466.80%
Nov 13, 2024
Reiterates: Buy
Price Target: $30
Current: $9.92
Upside: +202.57%
Nov 12, 2024
Reiterates: Buy
Price Target: $12
Current: $0.83
Upside: +1,338.85%
Nov 11, 2024
Maintains: Buy
Price Target: $8 → $4
Current: $1.15
Upside: +247.83%
Nov 11, 2024
Maintains: Buy
Price Target: $14 → $12
Current: $0.84
Upside: +1,322.98%
Nov 11, 2024
Reiterates: Neutral
Price Target: $6
Current: $2.42
Upside: +148.45%
Nov 11, 2024
Maintains: Buy
Price Target: $22 → $18
Current: $2.79
Upside: +546.32%
Nov 8, 2024
Maintains: Buy
Price Target: $95 → $115
Current: $92.00
Upside: +25.01%
Nov 6, 2024
Maintains: Buy
Price Target: $55 → $52
Current: $22.70
Upside: +129.07%
Nov 6, 2024
Reiterates: Buy
Price Target: $8
Current: $3.96
Upside: +102.18%
Nov 6, 2024
Reiterates: Neutral
Price Target: $20
Current: $16.26
Upside: +23.04%
Oct 24, 2024
Reiterates: Buy
Price Target: $65
Current: $24.85
Upside: +161.57%
Sep 23, 2024
Reiterates: Buy
Price Target: $6
Current: $1.51
Upside: +297.35%
Sep 6, 2024
Reiterates: Buy
Price Target: $8
Current: $1.06
Upside: +654.79%
Apr 25, 2024
Reiterates: Neutral
Price Target: n/a
Current: $3.35
Upside: -